Cox regression analysis of factors associated with survival in all NB patients from the discovery set
| Factors | Univariate | Multivariate | ||
| HR (95% CI) | P value | HR (95% CI) | P value | |
| OS | ||||
| Age, months (>18 vs <18) | 12.48 (3.87 to 40.22) | <0.001 | 6.17 (1.78 to 21.29) | 0.004 |
| INSS (advanced vs early) | 6.10 (2.19 to 17.00) | <0.001 | 1.95 (0.65 to 5.84) | 0.231 |
| MYCN (amplified vs non-amplified) | 2.47 (1.30 to 4.68) | 0.006 | 1.29 (0.65 to 2.57) | 0.457 |
| Grade (undifferentiated or poorly vs well) | 1.90 (1.08 to 3.35) | 0.026 | 1.69 (0.93 to 3.07) | 0.085 |
| MKI (high vs non-high) | 1.69 (0.60 to 4.73) | 0.313 | ||
| ICS (high vs low) | 1.21 (1.15 to 1.27) | <0.001 | 1.18 (1.12 to 1.25) | <0.001 |
| EFS | ||||
| Age, months (>18 vs <18) | 3.97 (2.26 to 6.95) | <0.001 | 2.19 (1.20 to 4.00) | 0.010 |
| INSS (advanced vs early) | 6.71 (3.09 to 14.57) | <0.001 | 4.01 (1.75 to 9.17) | 0.001 |
| MYCN (amplified vs non-amplified) | 1.94 (1.16 to 3.24) | 0.011 | 1.04 (0.62 to 1.76) | 0.879 |
| Grade (undifferentiated or poorly vs well) | 1.30 (0.84 to 2.01) | 0.225 | ||
| MKI (high vs non-high) | 1.06 (0.56 to 2.02) | 0.840 | ||
| ICS (high vs low) | 1.14 (1.10 to 1.19) | <0.001 | 1.11 (1.07 to 1.16) | <0.001 |
Statistically significant p values are shown in bold.
. EFS, event-free survival; ICS, immune checkpoint-based signature; INSS, the International Neuroblastoma Staging System; NB, neuroblastoma; OS, overall survival.